MAPT and frontotemporal dementia: We have recently demonstrated that the inverse agonist SB-269970, which specifically blocks the constitutive activity of 5-HT7R, reduces pathological tau hyperphosphorylation and aggregation, and alleviates toxicity in neural cells induced by overexpression of an FTD-associated tau mutant.72